ORONSKY ARNOLD L 4/A
4/A · PMV Pharmaceuticals, Inc. · Filed Oct 2, 2020
Insider Transaction Report
Form 4/AAmended
ORONSKY ARNOLD L
Director10% Owner
Transactions
- Purchase
Common Stock
2020-09-25$18.00/sh+55,555$999,990→ 55,555 total(indirect: See footnote) - Conversion
Common Stock
2020-09-29+1,620,101→ 1,675,656 total(indirect: See footnote) - Conversion
Common Stock
2020-09-29+3,488,398→ 5,164,054 total(indirect: See footnote) - Conversion
Series Seed Preferred Stock
2020-09-29−1,620,101→ 0 total(indirect: See footnote)→ Common Stock (1,620,101 underlying) - Conversion
Series B Preferred Stock
2020-09-29−1,040,654→ 0 total(indirect: See footnote)→ Common Stock (1,040,654 underlying) - Conversion
Series C Preferred Stock
2020-09-29−265,203→ 0 total(indirect: See footnote)→ Common Stock (265,203 underlying) - Conversion
Common Stock
2020-09-29+1,040,654→ 6,204,708 total(indirect: See footnote) - Conversion
Common Stock
2020-09-29+265,203→ 6,469,911 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2020-09-29−3,488,398→ 0 total(indirect: See footnote)→ Common Stock (3,488,398 underlying)
Footnotes (2)
- [F1]The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
- [F2]The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.